Genetic Modifiers of Stroke in Patients with Sickle Cell Disease—A Scoping Review
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126317 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Morohuntodun O Oni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Stroke, Genome-Wide Association Study, Genetic Predisposition to Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H&TRC, FCT/MCTES, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Talent Development Award.
Themen: Schlaganfall
Abstract (Originalsprache)
Sickle cell disease (SCD) clinically manifests itself with a myriad of complications. Stroke, both ischemic and hemorrhagic, as well as silent white matter changes, occurs at a relatively high prevalence. Understanding why and in whom stroke is most likely to occur is critical to the effective prevention and treatment of individuals with SCD. Genetic studies, including genome- and exome-wide association studies (GWAS and EWAS), have found several key modifiers associated with increased stroke/stroke risk in SCD via mechanisms including Hemoglobin F (HbF) modulation, inflammation, cellular adhesion, endothelial disruption, and hemolysis. We present a review on the modifiers that have most clearly demonstrated an association to date. More studies are needed to validate other potential polymorphisms and identify new ones. Incorporating gene-focused screenings in clinical care could provide avenues for more targeted, more effective, and less toxic prevention of stroke in this population. The data from this review will be used to inform the initial GWAS performed by the International Hemoglobinopathy Research Network (INHERENT) consortium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02115, USA.
- H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, 1990-092 Lisbon, Portugal.
- Medical Library, Boston Children's Hospital, Boston, MA 02115, USA.
ORCID-Profile: Miguel Brito
Förderung
- H&TRC, FCT/MCTES
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Talent Development Award
Zitieren
APA
Oni, M. O., Brito, M., Rotman, C., Archer, N. M., & International Hemoglobinopathy Research Network (INHERENT) (2024). Genetic Modifiers of Stroke in Patients with Sickle Cell Disease—A Scoping Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126317
Vancouver
Oni MO, Brito M, Rotman C, Archer NM, International Hemoglobinopathy Research Network (INHERENT). Genetic Modifiers of Stroke in Patients with Sickle Cell Disease—A Scoping Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126317
BibTeX
@article{Oni2024,
author = {Oni, Morohuntodun O and Brito, Miguel and Rotman, Chloe and Archer, Natasha M and International Hemoglobinopathy Research Network (INHERENT), International Hemoglobinopathy Research Network (INHERENT)},
title = {Genetic Modifiers of Stroke in Patients with Sickle Cell Disease—A Scoping Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126317}
}
EUVIMED